sc-43
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2018 (NCT03443622)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Protein-tyrosine phosphatase 1CACTIVATOR
PTPN6 activator
Chemistry & pharmacology
Loading structure…
SMILES
N#Cc1ccc(Oc2cccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c2)cc1- Mol. weight
- 431.8 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2063215 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04733521 | Phase 1/Phase 2 (Phase 2) | May 1, 2021 | Chonnam National University, RAND Corporation |
| NCT03443622 | Phase 1 | Nov 30, 2018 | SupremeCure Pharma Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chonnam National University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| RAND Corporation | For profit | 1 | 1 | 1 | 2021 |
| SupremeCure Pharma Inc. | For profit | 1 | 1 | 1 | 2018 |
3 organizations
Page 1 / 1